-
Health leaders urge public to have symptoms checked on World Cancer Day
pharmatimes
February 05, 2021
Health and Social Care Secretary Matt Hancock and NHS Clinical Director for Cancer Peter Johnson have called on the public to contact their GP if they have symptoms of cancer to coincide with World Cancer Day.
-
NCCN Gets Personal About Improving Global Cancer Care for World Cancer Day
prnasia
February 04, 2021
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—joins people and organizations worldwide in commemorating World Cancer Day every February 4.
-
AstraZeneca and UCL to collaborate on two immuno-oncology projects
pharmatimes
February 04, 2021
British drugmaker and researchers from the UCL Division of Infection & Immunity will collaborate on two projects which will aim to contribute to the development of new cancer treatments.
-
Speedy Detection of 13 Cancer Types using a Tiny Amount of Blood: microRNA Detection Technology
prnasia
January 27, 2021
Globally, about 1 in 6 deaths is due to cancer. With advances in treatment, early detection and treatment of cancer greatly improves survival rates of patients.
-
Research finds decrease in radiotherapy treatments due to COVID-19
pharmatimes
January 27, 2021
New research has revealed ‘dramatic changes’ in the delivery of radiotherapy treatments for cancer during the first wave of the COVID-19 pandemic in England.
-
United Immunity and Xyphos, an Astellas Company, to Collaborate on Next Generation Nano-Immunotherapies for Cancer Treatment
prnasia
January 15, 2021
United Immunity, Co., Ltd. has entered into a joint research agreement as of December 2020 with Xyphos Biosciences, Inc., (California, US), a subsidiary of Astellas Pharma Inc. (Tokyo, Japan).
-
First Patient Dosed in Biomarker-Guided Study of DB102 for Newly-Diagnosed Glioblastoma
americanpharmaceuticalreview
January 15, 2021
Denovo Biopharma announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma ...
-
Sanofi, Israel’s Biond Biologics to team up for new cancer drug
expresspharma
January 15, 2021
Biond said that it will receive a $125 million upfront payment in cash under the deal.
-
Xencor, MD Anderson enter collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of cancer
pharmaceutical-business-review
January 13, 2021
Xencor and The University of Texas MD Anderson Cancer Center announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
-
Boehringer Ingelheim, Enara Bio sign pact to discover novel shared antigens for cancer immunotherapies
expresspharma
January 13, 2021
Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen discovery platform.